Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate

Maturitas

Volumn 64, Issue 3, 2009, Pages 188-192

  Muñoz Torres, Manuel ^a,d   Reyes García, Rebeca ^a   Mezquita Raya, Pedro ^b   Fernández García, Diego ^a   Alonso, Guillermo ^a   Dios Luna, Juan de ^c   Ruiz Requena, María Estrella ^a   Escobar Jiménez, Fernando ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b HOSPITAL TORRECÁRDENAS   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d Plataforma Metabolismo Mineral y Óseo ^*  (Spain)

Author keywords

Alendronate; Cathepsin K; Postmenopausal Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; OSTEOCALCIN;

ADULT; ARTICLE; BONE METABOLISM; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

ADULT; AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; CATHEPSIN K; COLLAGEN TYPE I; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PREMENOPAUSE; REFERENCE VALUES; YOUNG ADULT;

EID: 70350591051     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.09.011     Document Type: Article

References (21)

1. Garnero P., Borel O., Byralsen I., et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem 273 (1998) 32347-32352
2. Zaidi M., Troen B., Moonga B.S., and Abe E. Cathepsin K, osteoclastic resorption, and osteoporosis therapy. J Bone Miner Res 16 (2001) 1747-1749
3. Kumar S., Dare L., Vasko-Moser J.A., et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone 40 (2007) 122-131
4. Fratzl-Zelman N., Valenta A., Roshger P., et al. Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J Clin Endocrinol Metab 89 (2004) 1538-1547
5. Saftig P., Hunzinger E., Wehmeyer O., et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K deficient mice. Proc Natl Acad Sci USA 95 (1998) 13453-13458
6. Henriksen K., Tanko L.B., Qvist P., Delmas P.D., Christiansen C., and Karsdal M.A. Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18 (2007) 681-685
7. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21 (2000) 115-137
8. Garnero P., Sornay-Rendu E., Claustrat B., and Delmas P.D. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15 (2000) 1526-1536
9. Chapurlat R.D., and Delmas P.D. Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab 2 (2006) 211-219
10. Plotkin L.I., Manolagas S.C., and Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39 (2006) 443-452
11. Black D.M., Thompson D.E., Bauer D.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 85 (2000) 4118-4123
12. Kerschan-Schindl K., Hawa G., Kudlacek S., Woloszczuk W., and Pietschmann P. Serum levels of cathepsin K decrease with age in both women and men. Exp Gerontol 40 (2005) 532-535
13. Holzer G., Noske H., Lang T., Holzer L., and Willinger U. Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures?. J Lab Clin Med 146 (2005) 13-17
14. Meier C., Meinhardt U., Greenfield J.R., et al. Serum cathepsin K reflects osteclastic activity in women with postmenopausal osteoporosis and patients with Pagets disease. Clin Lab 52 (2006) 1-10
15. Genant H.K., and Jergas M. Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporos Int 14 Suppl 3 (2003) S43-S55
16. Seibel M.J. Biochemical markers of bone turnover: part I: Biochemistry and variability. Clin Biochem Rev 26 (2005) 97-122
17. Nenonen A., Cheng S., Ivaska K.K., et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20 (2005) 1804-1812
18. Christgau S., Bitsch-Jensen O., Hanover Bjarnason N., et al. Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26 (2000) 505-511
19. Tanaka S., Miyazaki T., Fukuda A., et al. Molecular mechanism of the life and death of the osteoclast. Ann N Y Acad Sci 1068 (2006) 180-186
20. Chu P., Chao T.Y., Lin Y.F., Janckila A.J., and Yam L.T. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 41 (2003) 1052-1059
21. Alatalo S.L., Halleen J.M., Hentunen T.A., Monkkonen J., and Vaananen H.K. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 46 (2000) 1751-1754